Berenberg analyst Luisa Hector raised the firm’s price target on AstraZeneca (AZN) to 160 GBp from 145 GBp and keeps a Buy rating on the shares.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s AZD3974 Enters Early Human Testing: What Investors Should Watch
- AstraZeneca’s AZD1163 Clears Early Safety Hurdle: What Phase I Completion Means for Investors
- AstraZeneca initiated with a Buy at Citi
- AstraZeneca Sharpens Andexanet Strategy With New Phase I Dosing Study
- AstraZeneca Halts Early Heart Drug Study: What It Means for AZN Investors